Financial Performance - The company's revenue for Q1 2023 was ¥170,479,038, a decrease of 14.56% compared to ¥199,539,234 in the same period last year[5]. - Net profit attributable to shareholders was ¥12,394,500, down 21.87% from ¥15,863,012 in Q1 2022[5]. - Total operating revenue for the current period is ¥170,479,038, a decrease of 14.6% from ¥199,539,234 in the previous period[20]. - Net profit for the current period is ¥12,394,500.46, a decline of 21.6% compared to ¥15,863,012.65 in the previous period[21]. - The company reported a total profit of ¥13,710,136.23, down from ¥17,933,569.31 in the previous period[21]. - Basic and diluted earnings per share are both ¥0.18, compared to ¥0.22 in the previous period[21]. Cash Flow and Investments - The net cash flow from operating activities decreased by 76.95%, amounting to ¥4,831,414.87 compared to ¥20,964,247.56 in the previous year[10]. - The company experienced a 105.01% increase in cash outflow from investing activities, amounting to -¥13,887,070.18 due to higher fixed asset investments[10]. - Operating cash flow net amount is ¥4,831,414.87, significantly down from ¥20,964,247.56 in the previous period[23]. - Cash and cash equivalents at the end of the period were CNY 544,003,174.24, slightly down from CNY 553,058,829.55[17]. - Cash and cash equivalents at the end of the period are ¥544,003,174.24, down from ¥679,032,171.26 at the end of the previous period[24]. Assets and Liabilities - Total assets increased by 1.86% to ¥1,420,386,494.43 from ¥1,394,430,627.65 at the end of the previous year[5]. - Current assets totaled CNY 814,424,221.20, up from CNY 788,373,543.53, indicating an increase of about 3.67%[17]. - Total liabilities increased to CNY 161,084,374.30 from CNY 147,523,007.98, marking an increase of approximately 9.67%[18]. - The total equity attributable to shareholders of the parent company reached CNY 1,259,302,120.13, up from CNY 1,246,907,619.67, reflecting a growth of about 0.41%[19]. Receivables and Prepayments - Accounts receivable rose by 26.90% to ¥66,867,826.33, primarily due to a higher amount of receivables still within the credit period[8]. - Accounts receivable rose to CNY 66,867,826.33 from CNY 52,694,889.30, representing a significant increase of approximately 26.87%[17]. - Prepayments surged by 317.71% to ¥6,893,818.98, mainly due to increased advance payments for raw materials[8]. - The company reported a significant increase in prepayments, which rose to CNY 6,893,818.98 from CNY 1,650,372.13, an increase of approximately 318.66%[17]. Operating Costs and Expenses - Total operating costs decreased to ¥156,987,177.98, down 13.8% from ¥182,199,147.28 in the previous period[20]. - Research and development expenses increased to ¥5,829,707.18, up from ¥5,079,329.93 in the previous period[20]. - Sales expenses decreased to ¥168,387.89 from ¥214,091.43 in the previous period[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,546[11]. - The report indicates no changes in the number of preferred shareholders and limited changes in restricted shares, suggesting stability in shareholder structure[14]. Other Observations - The company reported a significant increase in tax and additional fees by 187.75%, totaling ¥1,528,267.50 compared to ¥531,108.21 in the previous year[9]. - The weighted average return on equity decreased to 0.99% from 1.30% year-on-year[5]. - The company's short-term borrowings and other financial liabilities were not detailed in the provided data, indicating a focus on operational liquidity management[18]. - The company has not reported any new product developments or market expansions in this quarter[25].

Financial Performance - The company's revenue for Q3 2022 reached ¥172,277,422.57, representing a 15.85% increase compared to the same period last year, and a total revenue of ¥597,167,430.98 for the year-to-date, up 24.99%[5] - Net profit attributable to shareholders for Q3 2022 was ¥10,240,205.46, a slight increase of 0.25% year-on-year, while the year-to-date net profit reached ¥51,763,132.22, up 13.54%[5] - Total operating revenue for Q3 2022 reached ¥597,167,430.98, an increase of 25.0% compared to ¥477,774,804.52 in Q3 2021[21] - Operating profit for the period was ¥57,642,155.34, up from ¥50,205,198.49 in the same period last year, reflecting a growth of 4.3%[22] - Net profit attributable to shareholders of the parent company was ¥51,763,132.22, representing a 13.5% increase from ¥45,590,862.44 in Q3 2021[22] Earnings and Shares - The basic earnings per share for Q3 2022 decreased by 26.32% to ¥0.14, with a year-to-date figure of ¥0.73, down 15.12%[5] - The basic earnings per share for Q3 2022 was ¥0.73, down from ¥0.86 in the previous year, reflecting a decrease of 15.1%[22] - The total number of common shareholders at the end of the reporting period is 10,601[13] - The largest shareholder, Wu Zhengjie, holds 24.18% of the shares, totaling 17,090,000 shares[13] - The total number of restricted shares at the end of the period is 40,387,500, with 13,300,000 shares released from restrictions during the period[14] Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥1,380,010,918.80, reflecting a 1.74% increase from the end of the previous year[5] - Total assets increased to ¥1,380,010,918.80, compared to ¥1,356,444,633.92 at the end of Q3 2021, marking a growth of 1.7%[20] - Total liabilities decreased to ¥141,434,367.26 from ¥144,893,214.60, a reduction of 2.5% year-over-year[20] - The company's total equity attributable to shareholders increased by 2.23% to ¥1,238,576,551.54 compared to the end of the previous year[5] Cash Flow - The cash flow from operating activities for the year-to-date was ¥13,978,347.65, showing a significant decline of 50.06% compared to the previous year[10] - The net cash flow from operating activities for the current period is ¥13,978,347.65, a decrease of 50.1% compared to ¥27,988,252.54 in the previous period[23] - Cash inflow from operating activities totaled ¥292,899,757.61, up 76.2% from ¥166,045,852.20 in the previous period[23] - Cash outflow from operating activities increased to ¥278,921,409.96, compared to ¥138,057,599.66 in the previous period, representing a 102.5% increase[23] - The net cash flow from investing activities is -¥107,189,528.51, which is a 93.5% increase in outflow compared to -¥55,274,028.84 in the previous period[24] - The net cash flow from financing activities is -¥25,004,964.89, a significant decrease from a net inflow of ¥658,554,260.13 in the previous period[24] - The total cash and cash equivalents at the end of the period is ¥546,639,544.90, down from ¥674,648,697.36 at the end of the previous period[24] - The company received cash from investment totaling ¥726,016,000.00 during the financing activities[24] - The company paid out ¥24,776,164.64 in dividends and interest during the financing activities, compared to ¥1,629,664.40 in the previous period[24] Research and Development - The company reported a 43.58% increase in R&D expenses, totaling ¥18,273,424.74 for the year-to-date, attributed to rising personnel costs and external development fees[9] - Research and development expenses rose to ¥18,273,424.74, up 43.7% from ¥12,727,267.98 in Q3 2021, indicating a focus on innovation[21] - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[16] Investments and Acquisitions - The net cash flow from investment activities was negative at -¥107,189,528.51, a 93.92% increase in outflows due to the acquisition of land use rights by a wholly-owned subsidiary[12] - The company acquired land use rights for ¥92.4 million for a specific plot of land[15] - The company is exploring market expansion opportunities, as indicated by its acquisition of land for development purposes[15] Other Financial Metrics - The company received government subsidies amounting to ¥1,962,457.55 in Q3 2022, contributing to a total of ¥6,019,203.52 for the year-to-date[7] - The company's cash and cash equivalents decreased from ¥664,855,690.65 at the beginning of the year to ¥546,639,544.90 by September 30, 2022, a decline of approximately 17.7%[18] - Accounts receivable increased from ¥47,987,148.55 to ¥54,797,718.61, representing an increase of about 14.9%[18] - The total current assets decreased from ¥872,928,045.58 to ¥795,627,204.96, a reduction of approximately 8.9%[18] - Deferred tax assets remained stable at ¥5,726,232.72, slightly down from ¥5,740,991.53 in Q3 2021[20] - The company reported a financial expense of -¥12,608,809.02, a significant improvement compared to ¥964,458.92 in Q3 2021, indicating better financial management[21] - The company reported a significant increase in cash received from other operating activities, totaling ¥19,364,603.23, compared to ¥6,067,787.92 in the previous period[23]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥424,890,008.41, representing a 29.12% increase compared to ¥329,072,713.05 in the same period last year [22]. - Net profit attributable to shareholders was ¥41,522,926.76, up 17.38% from ¥35,375,814.24 year-on-year [22]. - The net cash flow from operating activities increased by 35.61% to ¥36,377,005.42, compared to ¥26,824,045.40 in the previous year [22]. - The company's total assets at the end of the reporting period were ¥1,389,788,863.18, a 2.46% increase from ¥1,356,444,633.92 at the end of the previous year [22]. - The weighted average return on net assets decreased to 3.37%, down 3.83% from 7.20% in the previous year [22]. - The company's operating revenue for the reporting period was ¥424,890,008.41, representing a year-on-year increase of 29.12% due to higher sales volume and increased selling prices [61]. - Operating costs rose to ¥359,898,650.49, a 34.73% increase compared to the previous year, primarily driven by increased sales volume and rising raw material prices [61]. - The gross profit margin for the main product category 1501 was 12.27%, down 5.16% from the previous year, indicating increased cost pressures [64]. Research and Development - The company focuses on the R&D, production, and sales of pharmaceutical intermediates, pesticide intermediates, and new material intermediates, emphasizing innovation and clean production processes [30]. - The company holds 20 invention patents, 6 utility models, and 6 software copyrights, reflecting its strong focus on innovation and technology development [51]. - Research and development expenses increased by 35.24% to ¥11,198,752.61, mainly due to higher salaries for R&D personnel [62]. - The company aims to increase its R&D investment by 20% in the upcoming fiscal year to support innovation and technology advancements [192]. Environmental Management - The company emphasizes a "clean production first" approach, resulting in reduced waste and effective cost control during the synthesis process [52]. - Environmental management efforts included compliance with national policies and significant investments in green technology, supporting sustainable development goals [59]. - The company has a wastewater treatment capacity of 1000 tons per day and a waste gas treatment system with a capacity of 25,000 m³/h, ensuring compliance with environmental standards through online monitoring systems [108]. - The company has established a comprehensive environmental risk emergency mechanism and has filed an emergency response plan with the environmental protection department [110]. - The company has not faced any administrative penalties for environmental issues during the reporting period, indicating compliance with environmental regulations [112]. - The company is committed to enhancing its environmental protection measures through research and technological improvements to reduce environmental risks [92]. Market Strategy and Operations - The company operates under the stock code 301065 on the Shenzhen Stock Exchange [17]. - The company operates under an "order-driven, moderate stocking" production model, aligning production plans with customer orders and market forecasts [46]. - The company has established long-term stable relationships with suppliers and has a raw material procurement control system in place [91]. - The company is responding to rising raw material prices, which have increased compared to the same period last year, impacting production costs [41]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth [192]. Corporate Governance - The financial report includes a commitment to ensure the accuracy and completeness of the financial statements by the management team [4]. - The company has a robust internal control system and governance structure to protect shareholder rights and ensure transparent information disclosure [116]. - The company has engaged in social responsibility initiatives, focusing on economic, environmental, and social performance [115]. - The company has not reported any issues or discrepancies in the use and disclosure of raised funds [79]. Shareholder Information - The company reported a profit distribution of 738 million yuan to shareholders, with no allocation to general risk reserves [190]. - Major shareholders include Wu Zhengjie with 24.18% and Chen Jianjun with 10.10% of the shares [155]. - The company has a total of 11,813 shareholders at the end of the reporting period [155]. - The company's shareholding structure includes 74.99% of restricted shares and 25.01% of unrestricted shares [153]. Risk Management - The company acknowledges the risk of performance decline due to macroeconomic factors, industry policies, and market competition, and plans to enhance profitability by expanding into new markets and customer segments [94]. - The ongoing COVID-19 pandemic presents uncertainties that could adversely impact the company's operations, prompting the company to closely monitor developments and cooperate with government measures [97]. - The company faces environmental protection risks due to the production of wastewater, waste gas, and solid waste, which may increase costs related to environmental facilities and waste management [92]. Future Outlook - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, indicating a focus on reinvestment [103]. - Future outlook remains positive with expectations of continued growth in revenue and market expansion strategies [199]. - The company has initiated a strategic review of potential mergers and acquisitions to enhance its competitive position in the market [192].

Financial Performance - The company's operating revenue for Q1 2022 was ¥199,539,234.33, representing a 25.49% increase compared to ¥159,008,572.39 in the same period last year[4] - The net profit attributable to shareholders was ¥15,863,012.65, a 1.78% increase from ¥15,585,709.28 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,845,270.62, up 10.55% from ¥13,428,712.16 in the previous year[4] - Operating profit for the current period was ¥17,986,359.31, a slight increase of 5.2% from ¥16,141,361.29 in the previous period[22] - Net profit for the current period was ¥15,863,012.65, representing a 1.8% increase from ¥15,585,709.28 in the prior period[23] - The company’s total profit for the current period was ¥17,933,569.31, slightly down from ¥18,073,544.01 in the previous period[22] Earnings and Returns - The basic earnings per share decreased by 24.14% to ¥0.22 from ¥0.29 in the same period last year[5] - The weighted average return on equity fell to 1.30% from 3.24% year-on-year, a decrease of 1.94%[5] - The company reported a decrease in basic and diluted earnings per share to ¥0.22 from ¥0.29 in the previous period[23] Cash Flow and Assets - The company's cash flow from operating activities was ¥20,964,247.56, down 3.45% from ¥21,713,075.04 in the same period last year[4] - Cash flow from operating activities generated a net amount of ¥20,964,247.56, compared to ¥21,713,075.04 in the previous period[27] - Cash and cash equivalents at the end of the period totaled ¥679,032,171.26, significantly up from ¥28,658,323.70 at the end of the previous period[27] - The company's cash and cash equivalents increased to CNY 679,032,171.26 from CNY 664,855,690.65, reflecting a growth of approximately 2%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,358,805,261.43, a slight increase of 0.17% from ¥1,356,444,633.92 at the end of the previous year[5] - As of March 31, 2022, the total assets of Zhejiang Benli Technology Co., Ltd. amounted to CNY 1,358,805,261.43, a slight increase from CNY 1,356,444,633.92 at the beginning of the year[18] - Total liabilities decreased to CNY 131,057,817.78 from CNY 144,893,214.60, a reduction of about 9.5%[19] - The company's equity attributable to shareholders increased to CNY 1,227,747,443.65 from CNY 1,211,551,419.32, showing a growth of approximately 1.3%[19] Expenses - Total operating costs amounted to ¥182,199,147.28, up 28.0% from ¥142,287,763.49 in the prior period[21] - Research and development expenses increased to ¥5,079,329.93, up 27.0% from ¥4,000,288.26 in the previous period[22] - The company's sales expenses decreased significantly by 76.54% to ¥214,091.43 from ¥912,690.02 year-on-year, due to the reclassification of transportation costs[11] Other Developments - The company established a wholly-owned subsidiary, Linhai Benli Technology Co., Ltd., and completed the registration on April 19, 2022[15] - The company plans to utilize raised funds and self-owned funds for land use rights acquisition and infrastructure construction[15] - The company reported a significant increase in prepayments, which rose to CNY 14,187,661.82 from CNY 3,262,775.76, marking an increase of over 335%[17] - Accounts receivable rose to CNY 55,674,982.03 from CNY 47,987,148.55, indicating an increase of about 16%[17] - Inventory decreased to CNY 97,668,507.04 from CNY 109,160,315.72, representing a decline of approximately 10.5%[17] - Accounts receivable financing decreased by 35.54% to ¥28,333,217.99 from ¥43,951,786.77, primarily due to increased bank acceptance bill endorsements[9] - The company’s non-current assets totaled CNY 482,845,646.87, slightly down from CNY 483,516,588.34[18]

Financial Performance - The company's operating revenue for 2021 was ¥621,104,645.37, a decrease of 0.60% compared to ¥624,844,002.36 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥54,824,924.50, down 40.22% from ¥91,713,772.26 in 2020[21]. - The net cash flow from operating activities decreased by 63.38% to ¥36,016,520.54 in 2021 from ¥98,364,349.70 in 2020[21]. - The total assets at the end of 2021 were ¥1,356,444,633.92, an increase of 113.40% from ¥635,637,496.97 at the end of 2020[21]. - The net assets attributable to shareholders increased by 155.89% to ¥1,211,551,419.32 at the end of 2021 from ¥473,471,257.00 at the end of 2020[21]. - The basic earnings per share for 2021 was ¥0.95, a decrease of 45.09% from ¥1.73 in 2020[21]. - The company reported a total of ¥5,455,799.05 in non-recurring gains and losses for 2021, compared to ¥2,147,731.57 in 2020[26]. - Total revenue for 2021 was ¥621,104,645.37, a decrease of 0.60% compared to ¥624,844,002.36 in 2020[72]. - Revenue from pharmaceutical intermediates was ¥606,825,884.34, accounting for 97.70% of total revenue, down 0.81% year-on-year[72]. - Revenue from product 1701 increased significantly by 86.43% to ¥67,328,318.61, while revenue from product 1201 decreased by 11.75% to ¥62,794,159.32[72]. - The gross profit margin for pharmaceutical intermediates was 16.53%, down 7.78% from the previous year[74]. Dividend Distribution - The company reported a profit distribution plan of cash dividends of 3.50 RMB per 10 shares, totaling 246 million RMB based on 70,680,000 shares[5]. - The cash dividend represents 100% of the total distributable profit of 341,365,170.98 yuan[178]. - The total number of shares for the dividend distribution is based on 70,680,000 shares, with no stock dividends or capital reserve transfers planned[178]. - The remaining undistributed profits will be carried forward to the next fiscal year[178]. Research and Development - The company focuses on the research, production, and sales of pharmaceutical intermediates, pesticide intermediates, and new material intermediates[30]. - The company aims to replace traditional processes with safe, environmentally friendly, and economical synthetic processes in the chemical intermediate industry[30]. - The company has established a continuous innovation mechanism driven by market demands, emphasizing independent research and development, and collaboration with external research forces[43]. - The company aims to strengthen its R&D investment and technical innovation to meet customer demands and increase market share of existing products[112]. - The number of R&D personnel increased by 5.77% to 55, while the proportion of R&D personnel to total staff slightly decreased to 13.06%[85]. Market Expansion and Sales Strategy - The company is actively pursuing market expansion opportunities, leveraging its technological advancements to enhance competitive positioning[14]. - The sales strategy primarily targets the domestic market, with exports to India and Japan, utilizing direct sales and trade partnerships[49]. - The company adopts an "order-driven, moderate stocking" production model, adjusting production plans based on customer orders and market forecasts[45]. - The company plans to focus on market expansion by deepening cooperation with existing customers and exploring new market opportunities through exhibitions[116]. Environmental Responsibility - The report indicates a comprehensive approach to environmental responsibility, including waste management and reduction strategies[14]. - The company aims to enhance resource utilization efficiency and reduce pollution through clean production practices[14]. - The company emphasizes clean production, achieving high atomic utilization rates and minimal waste generation during the synthesis process[60][61]. - The company has implemented energy management measures to reduce carbon emissions, contributing to sustainable development[194]. - The company has established a comprehensive environmental risk emergency mechanism and filed an emergency response plan with the environmental protection department[192]. Governance and Compliance - The financial report includes a commitment to transparency, with all board members present during the report's approval[4]. - The company maintains a robust governance structure, ensuring compliance with relevant laws and regulations, and promoting transparency in operations[133]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[134]. - The company has established independent operational management structures, ensuring no overlap with controlling shareholders or related enterprises[144]. - The company has not reported any related party transactions that could lead to conflicts of interest during the reporting period[145]. Operational Risks and Challenges - The company emphasized the importance of risk awareness regarding forward-looking statements in the annual report, highlighting potential operational risks and corresponding countermeasures[5]. - Future performance may be impacted by macroeconomic conditions, industry policies, technological advancements, and market competition, leading to potential risks of performance decline[125]. - The complex international situation and domestic economic slowdown create uncertainties that could affect the company's operations[126]. - The ongoing COVID-19 pandemic poses significant risks to global economic development and the company's production activities[129]. Production Capacity and Efficiency - The company has established three major technology platforms for synthetic technology, focusing on carbonylation reaction, chlorination reaction, and green synthesis of quinolone raw materials[14]. - The production capacity utilization rates for major products are as follows: Product 801 at 95.59%, Product 1201 at 88.69%, and Product 1501 at 76.30%[52][53]. - The company has completed the construction of 5,203 tons/year capacity for Product 1201 and 6,100 tons/year for Product 1501, both are currently operational[53]. - The company is currently constructing an additional 3,000 tons/year capacity for Product 801, which is expected to enhance production capabilities[52]. Employee Management and Training - The total number of employees at the end of the reporting period was 421, with 316 in production, 55 in technical roles, and 38 in administration[171]. - The company has established a salary system that includes annual salary for middle and senior management, performance-based pay for technical staff, and piece-rate pay for production workers[173]. - The training plan for 2021 includes lean management training, safety education, and the development of a comprehensive course system for new employees and leadership training[174]. - The company emphasizes talent as a key factor for sustainable development, focusing on a fair, respectful, and diverse work environment[200].

Financial Performance - The company's revenue for Q3 2021 was ¥148,702,091.47, a decrease of 4.18% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2021 was ¥10,215,048.20, down 61.52% year-on-year[3]. - The net profit excluding non-recurring items for Q3 2021 was ¥8,804,255.75, a decline of 64.57% compared to the previous year[3]. - The basic earnings per share for Q3 2021 was ¥0.19, a decrease of 62.07% year-on-year[3]. - The net profit for Q3 2021 was CNY 45,590,862.44, a decrease of 31.2% compared to CNY 66,358,898.71 in Q3 2020[22]. - Operating profit for Q3 2021 was CNY 50,205,198.49, down 33.8% from CNY 75,791,982.67 in the same period last year[22]. - Total revenue from operating activities was CNY 159,969,745.28, a decline of 22.7% compared to CNY 206,917,206.82 in Q3 2020[25]. - The total comprehensive income for Q3 2021 was CNY 45,590,862.44, a decrease of 31.2% compared to CNY 66,358,898.71 in Q3 2020[23]. Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥1,338,953,800.38, representing a 110.65% increase from the end of the previous year[4]. - Total assets reached CNY 1,338,953,800.38, up from CNY 635,637,496.97 at the end of the previous year, representing a growth of 110.5%[19]. - Total liabilities decreased to CNY 136,636,443.12 from CNY 162,166,239.97, a reduction of 15.7%[19]. - Total liabilities reached CNY 162,166,239.97, down by CNY 5,468,475.27 from the last report[31]. - Current liabilities amounted to CNY 109,175,751.46, a decrease of CNY 2,372,710.31[31]. Equity - The equity attributable to shareholders increased by 153.94% to ¥1,202,317,357.26 compared to the end of the previous year[4]. - The company's equity attributable to shareholders increased to CNY 1,202,317,357.26 from CNY 473,471,257.00, reflecting a growth of 153.5%[19]. - The company's equity totaled CNY 473,471,257.00, remaining unchanged from the previous period[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥27,988,252.54, down 65.12% compared to the same period last year[11]. - The cash flow from operating activities for Q3 2021 was CNY 27,988,252.54, significantly lower than CNY 80,243,294.09 in Q3 2020[26]. - The company reported a significant increase in cash from financing activities, amounting to ¥658,554,260.13, a 12,353.08% increase year-on-year[11]. - The company raised CNY 726,016,000.00 through financing activities in Q3 2021, compared to no financing activities reported in Q3 2020[27]. - The company reported a cash and cash equivalents balance of CNY 674,648,697.36 at the end of Q3 2021, up from CNY 63,517,046.41 at the end of Q3 2020[27]. Accounts Receivable and Inventory - The company's accounts receivable increased by 50.78% to ¥58,713,482.50, attributed to sales growth and outstanding payments[7]. - Accounts receivable rose to CNY 58,713,482.50, compared to CNY 38,940,567.33 at the end of the previous year, marking a 50.9% increase[17]. - Inventory was valued at CNY 91,463,448.15, consistent with previous figures[30]. Research and Development - The company incurred research and development expenses of CNY 12,727,267.98 in Q3 2021, down from CNY 15,890,961.33 in the same period last year[22]. Future Strategies - Future strategies include potential market expansion and new product development, although specific details were not provided in the content[15]. Other Information - The company issued 17,680,000 shares in its initial public offering, increasing its total share capital to 70,680,000 shares[15]. - The company has not yet audited the third-quarter report[33]. - The report indicates that the company has adopted new leasing standards starting from 2021[33].